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From cloned DNA, neuraxin has been identified as a tubulin binding protein of predicted molecular weight of 94 kDa. The deduced sequence 
of the rat protein exhibits high homology to the C-terminal region of mouse microtubule-associated protein 5 (MAPS). Here, we show that different 
neuraxin antibodies recognize MAPS, but fail to detect a protein of 94 kDa, in subcellular and microtubular fractions of the rat central nervous 
system. Furthermore, tubulin binding by neuraxin was found to be dependent on taxol. These data are consistent with neuraxin corresponding 
to a C-terminal fragment of MAP5 that contains a low-affinity tubulin binding site. 
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1. INTRODUCTION 
Neuronal shape and cell surface differentiation de- 
pend on elaborate interactions of cytoskeletal and 
plasma membrane components. The elements me- 
diating these interactions in various compartments of 
the nerve cell have not been identified. Biochemical and 
immunological data, however, indicate that specialized 
membrane-associated proteins are implicated in the 
topological organization of adhesion proteins, ion 
channels and receptors at synapses, the nodes of Ran- 
vier, and along axons and dendrites (for examples see 
[l-3]). Upon screening for a cytoplasmic peripheral 
membrane protein associated with the inhibitory 
glycine receptor, we have isolated a cDNA which en- 
codes a novel putative structural protein, neuraxin [4]. 
Neuraxin has a predicted molecular weight of 94 kDa, 
contains a characteristic heptadecarepeat domain and is 
expressed in all regions of the central nervous system 
(CNS). Bacterial neuraxin fusion protein binds tubulin 
in the presence of taxol and cross-react with antibodies 
to microtubule-associated protein 5 (MAPS). Converse- 
ly, neuraxin antibodies recognize MAP5 on Western 
blots. Neuraxin therefore was suggested to represent a 
related or alternatively spliced variant of the MAP5 
protein family that may be implicated in membrane- 
cytoskeleton interactions [4]. 
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Previous work has established MAP5 (also termed 
MAPlB, MAP1.2, or MAPl-X) as a prominent large 
MAP (Mr about 250-300 kDa) that promotes tubulin 
polymerization in vitro and is highly expressed uring 
neurite outgrowth (reviewed in [5]). Recently, the 
primary structure of MAP5 has been unraveled by 
DNA sequencing [6]. Comparison of mouse MAP5 and 
rat neuraxin sequences now reveals that the open 
reading frame of the latter is highly homologous to the 
3 ’ coding region of the MAP5 cDNA (not shown). 
Throughout the coding sequences, 93% nucleotide 
identity are found. This raises the question whether 
MAP5 gene products corresponding to neuraxin indeed 
exist in the rodent CNS. Here, we present immunoblot- 
ting and microtubule copolymerization studies which 
indicate that the predicted neuraxin protein cor- 
responds to a C-terminal fragment of MAP5 harbour- 
ing a tubulin binding domain of low affinity. 
2. MATERIALS AND METHODS 
2.1. Antibodies 
The glycine receptor monoclonal antibody mAb 9b has been 
characterized previously [7]. Antisera raised against different do- 
mains of neuraxin were as described by Rienitz et al. 141. MAb aM5 
directed against MAP5 was obtained from H. Langbeheim, Sigma 
Immunochemicals. Horseradish peroxidase-conjugated anti-mouse 
and anti-rabbit IgG (goat) were purchased from Jackson Im- 
munoresearch Laboratories. 
2.2. Microtubule purification 
Microtubules were purified from rat brain at different developmen- 
tal stages (embryonic day 17 (E17), newborn (PO), 12 days after birth 
(P12), and adult) using the taxol method [8]. Synaptosomes and frac- 
tions thereof were prepared from brain and spinal cord according to 
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Gray and Whittaker [9], as modified by Wolf and Kapatos [lo]. A 
protease inhibitor cocktail [ 1 I] was included in all preparations. 
2.3. Gel electrophoresis and Western blot analysis 
Electrophoresis on 5-10% gradient SDS-polyacrylamide gels was 
performed according to Laemmli [12]. Protein bands were visualized 
using Coomassie brilliant blue R250 (Sigma). Transfer of proteins to 
nitrocellulose (Schleicher & Schuell, 0.45pm pore size) was performed 
according to Towbin et al. [13]. After transfer, blots were blocked for 
30 min in PBS supplemented with 5% (w/v) non-fat milk powder. In- 
cubation with the first antibody (diluted 1: 500 in PBS) was for 1.5 h 
at 35°C. After three washes in PBS, the blots were incubated with 
peroxidase-conjugated second antibody (diluted 1:2.000 in PBS) for 
1 h at 35°C. Antigen-antibody complexes were visualized by 
4-chloro-1-naphtol (Sigma). 
2.4. Copolymerization assay 
Tubulin was purified from rat brain microtubules using a 
phosphocellulose column [14] and stored at -70°C. Increasing 
amounts (2-10 p(g) of tubulin in MEM buffer (0.1 M MES-NaOH, 1 
mM EGTA, 1 mM MgS04, 1 mM dithiotreitol, pH 6.6) were mixed 
with 5 pg neuraxin-MS2 polymerase fusion protein, and GTP and tax- 
01 were added to final concentrations of 1 mM and 20,~M, respective- 
ly, After incubation for 30 min at 35°C the microtubules were cen- 
trifuged through a cushion of MEM buffer containing 10% (w/v) 
sucrose in a Beckmann airfuge (approx. 83 000 rpm for 10 min). Both 
supernatant and pellet were analyzed by SDS-polyacrylamide gel elec- 
trophoresis. Protein concentrations were determined according to 
Bradford [15]. 
3. RESULTS 
3.1. Western blof analysis of subcellularfractions from 
adult rat CNS 
Western blot analysis was performed to detect the 
possible presence of neuraxin in various subcellular 
fractions prepared from rat brain and spinal cord. The 
following antibodies were employed in these ex- 
periments: mAb 9b which recognizes the 93 kDa 
polypeptide associated with the postsynaptic glycine 
receptor [7], mAb aM5 directed against MAPS, and 
polyclonal antibodies raised against the head region 
(G15) or a repeat peptide (HPA 1) of the predicted 
neuraxin sequence [4]. These antibodies are known to 
react with a bacterially expressed neuraxin fusion pro- 
tein [4]. Fig. 1 shows a Western blot of subcellular frac- 
tions from spinal cord using the polyclonal antibody 
HPAl. 
All antibodies stained the neuraxin-MS2 polymerase 
fusion protein and a high-molecular weight component, 
which has previously been identified as MAP5 [4]. 
MAP5 was the only protein that was consistently la- 
belled on Western blots of subcellular fractions by all 
antibodies employed in this study. The HPAl an- 
tiserum in addition cross-reacted with polypeptides of 
about 75 and 30 kDa that were enriched in synap- 
tosomes (fig.1). However, a protein of relative elec- 
trophoretic mobility close to that of the predicted 
neuraxin protein was not found. We therefore conclude 
that neuraxin is not present in detectable amounts in the 
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Fig. 1. Anti-neuraxin antibodies detect MAPS, but not a 94 kDa pro- 
tein, in various fractions of rat spinal cord. Subcellular fractions were 
separated by SDS-polyacrylamide gel electrophoresis and subjected to 
Western blotting using the polyclonal antibody HPAl. Lane 1, 
neuraxin-MS2 polymerase fusion protein; 2, total homogenate; 3, 
100000 x g supernatant; 4, synaptosomal fraction. Microtubules 
were precipitated from the synaptosomal fraction using taxol, and 
supernatant; (5) and microtubular pellet (6) were analyzed as 
described above. Lanes 2-6 contained 1OOrg protein each, except lane 
3 where 500,~g were applied. Note that in addition to MAP5 and the 
neuraxin-MS2 polymerase fusion protein (arrows) the antibody 
decorates bands of about 75 kDa and 30 kDa that are enriched in 
synaptosomes. Similar data were obtained with subcellular fractions 
from rat brain (not shown). 
3.2. Analysis of microtubular fractions isolated at 
different stages of development 
To exclude the possibility that a protein correspond- 
ing to the open reading frame of the neuraxin cDNA is 
selectively expressed at specific developmental stages, 
as reported for the MAP2 protein family [ 16,171, addi- 
tional data were collected. Taxol-purified brain 
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Fig.2. Western blot analysis of rat brain microtubules isolated at dif- 
ferent developmental stages. Neuraxin-MS2 polymerase fusion pro- 
tein (lane 1) and taxol-purified microtubules isolated at El7 (2), PO 
(3), P12 (4) and adulthood (5) were analyzed by Western blotting us- 
ing antibodies Cl5 (A) and HPAl (B). Approximately equal amounts 
of tubulin were loaded per slot. Note the decrease of MPAS im- 
munoactivity with rat brain development (see [20]). Arrows indicate 
the positions of the neuraxin-MS2 polymerase fusion construct. 
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Fig.3. Copolymerization of the neuraxin-MS2 polymerase fusion pro- 
tein and tubulin requires taxol. The fusion protein was incubated in 
the absence (lanes 1, 2) or presence (3-8) of tubulin with (l-6) or 
without (7,s) taxol. After sedimentation, pellets (P) and supernatants 
(S) were separated on a 10% SDS-polyacrylamide gel followed by 
Coomassie blue staining. Tubulin concentrations per assay were 5 pg 
for 3 and 4, and 20 cg for 5-8, respectively. Note that only in the 
presence of taxol the neuraxin fusion construct was found in the pellet 
fractions (arrows). 
microtubules were isolated from rats of various ages 
and subjected to Western blot analysis using all an- 
tibodies mentioned above. Fig.2 illustrates the staining 
seen with the polyclonal antibodies Cl5 and HPAI. 
Only a single prominent high molecular weight band of 
electrophoretic mobility identical to that of MAP5 was 
consistently detected under these conditions. Similar 
data were obtained with the other antibodies (not 
shown). 
3.3. Tubulin binding of the neuraxin fusion protein 
requires taxol 
The tubulin binding capacity of neuraxin has been 
established previously in overlay experiments where 
tubulin was shown to bind a neuraxin-MS2 polymerase 
fusion protein in the presence of taxol [4]. Attempts to 
copolymerize purified tubulin with the neuraxin-MS2 
polymerase fusion protein in solution revealed that tax- 
01 was indeed required for incorporation of the fusion 
construct into microtubules (fig.3, lanes 3, 5). Even at 
tubulin concentrations high enough to allow self- 
polymerization [ 181, neuraxin was not incorporated in- 
to tubulin polymers without the alkaloid (fig.3, lane 7). 
Thus, tubulin binding by the neuraxin fusion protein 
appears to be taxol-dependent, suggesting a low affinity 
of the binding site(s) involved. 
4. DISCUSSION 
In this study, an attempt was made to identify the 
predicted neuraxin protein by Western blot analysis. 
Although four different antibodies reacting with a 
bacterially expressed neuraxin fusion protein were 
employed, a polypeptide of about 94 kDa was not 
found in various subcellular fractions of rat brain and 
spinal cord. Also, we failed to detect a polypeptide of 
this size in microtubules isolated at different stages of 
brain development. Only one of the antibodies, HPAl, 
which originally was generated by immunization with a 
peptide derived from the repeat domain of neuraxin, 
stained polypeptides of about 70 kDa and 30 kDa that 
were enriched in synaptosomes. The relation of these 
bands to neuraxin is presently unknown. All antibodies, 
however, visualized MAP5 in soluble and microtubular 
fractions. These data are consistent with neuraxin either 
representing a fragment of MAP5 or being an extremely 
rare microtubule-associated protein. In favour of the 
former possibility, an open reading frame extends in the 
neuraxin cDNA upstream of the predicted translation 
start site which matches that of mouse MAP5 up to 
position 12 of the neuraxin nucleotide sequence [4]. 
Co-assembly of neuraxin with tubulin polymers was 
found to require taxol. Only in the presence of the drug, 
incorporation of the neuraxin-MS2 polymerase fusion 
protein into microtubules was detected. This suggests a
low affinity of the observed association. Interestingly, 
transfection and copolymerization experiments using 
various deletion constructs have located the micro- 
tubule binding domain of MAP5 to a N-terminal basic 
repetitive region characterized by irregular KKEE(V/I) 
repeats [6]. This N-terminal domain is not present in the 
neuraxin sequence [4]. However, an accumulation of 
basic residues is found in the tail region close to the C- 
terminus of neuraxin/MAPS. Here, amphipathic cy- 
helical structures characterized by clusters of positive 
charges and hydrophobic amino acids have been 
predicted to form potential protein-protein interaction 
sites [4]. In vivo, this basic tail domain may constitute 
an additional low-affinity site involved in tubulin bin- 
ding and may be of potential importance for the cross- 
linking of filaments. Furthermore, the orientation of 
tyrosines in the repeat structure of neuraxin/MAPS 
suggests that these side chains are involved in 
hydrophobic interactions [4] similar to those suggested 
for another microtubule-associated protein, MAP2 
[19]. Here, deletion mutants have allowed mapping of 
the microtubule bundling activity to the hydrophobic 
C-terminal region of MAP2 [ 191. Future experiments of 
this type should show whether MAPS of unrelated se- 
quence, like MAP2 and MAPS, indeed share a similar 
topological organization of functional domains. 
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